Refocussing therapeutic strategies for cardiac arrhythmias: defining viable molecular targets to restore cardiac ion flux

Bibliography

• Health statistics and health information systems. Available from: http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls
   Google Scholar
• Lopshire JC, Zipes DP. Sudden cardiac death: better understanding of risks, mechanisms, and treatment. Circulation 2006;114:1134-6
   PubMedGoogle Scholar
• Zipes DP, Camm JA, Borgreffe M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death – executive summary. J Am Coll Cardiol 2006;48:e247-346
   PubMedGoogle Scholar
• Priori SG. Inherited arrhythmogenic diseases: the complexity beyond monogenic disorders. Circ Res 2004;94:140-5
   Google Scholar
• Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998;98:2334-51
   PubMed Web of Science ®Google Scholar
• Bers DM. Excitation–contraction coupling and contractile force (Ed.), Kluwer Academic Publishers, 2001;452
   Google Scholar
• Patentscope®. Available from: http://www.wipo.int/patentscope/en/
   Google Scholar
• Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006;5:1034-49
   PubMed Web of Science ®Google Scholar
• Trybulski EJ. Anti-arrhythmic agents. Exp Opin Ther Patents 1997;7:457-9
   Web of Science ®Google Scholar
• Anker SD, Jankowska EA, Okonko DO. Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002. Exp Opin Ther Patents 2004;14:639-54
   Web of Science ®Google Scholar
• Ashcroft FM. From molecule to malady. Nature 2006;440:440-7
   PubMed Web of Science ®Google Scholar
• George CH, Jundi H, Thomas NL, Fry DL, Lai FA. Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies. J Mol Cell Cardiol 2007;42:34-50
   PubMed Web of Science ®Google Scholar
• Marban E. Cardiac channelopathies. Nature 2002;415:213-8
   PubMed Web of Science ®Google Scholar
• George CH, Lai FA. Developing new anti-arrhythmics: clues from the molecular basis of cardiac ryanodine receptor (RyR2) Ca2+ release channel dysfunction. Curr Pharm Des 2007;13:3195-211
   Google Scholar
• Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006;113:305-15
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patient receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-4
   PubMed Web of Science ®Google Scholar
• Cast Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33
   PubMed Web of Science ®Google Scholar
• Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH. Preliminery results of the Cardiac Arrest Study Hambury (CASH). Am J Cardiol 1993;72:109F-113F
   PubMed Web of Science ®Google Scholar
• Waldo AL, Camm AJ, Deruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12
   PubMed Web of Science ®Google Scholar
• Burr ML, Ashfield-Watt PAL, Dunstan FDJ, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003;57:193-200
   PubMed Web of Science ®Google Scholar
• Avid Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40
   PubMed Web of Science ®Google Scholar
• Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVERT. J Am Coll Cardiol 2003;41:1707-12
   PubMed Web of Science ®Google Scholar
• Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8
   PubMed Web of Science ®Google Scholar
• Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997;337:1569-75
   PubMed Web of Science ®Google Scholar
• Medtronic, Inc. WO2007065123 (2007)
   Google Scholar
• Kaikkonen KS, Kortelainen ML, Linna E, Huikuri H. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006;114:1462-7
   PubMed Web of Science ®Google Scholar
• Dekker LRC, Bezzina CR, Henriques JPS, et al. Familial sudden death is an important risk factor for primary ventricular fibrillation. Circulation 2006;114:1140-5
   PubMed Web of Science ®Google Scholar
• Cast Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12
   PubMed Web of Science ®Google Scholar
• European Society of Cardiology Task Force. The Sicilian Gambit – a new approach to the classification of anti-arrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circ Res 1991;84:1831-51
   Google Scholar
• Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Camm AJ, Frangin G, et al. Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT). Eur Heart J 1994;15:620-4
   PubMed Web of Science ®Google Scholar
• Cairns JA, Connolly SJ, Roberts RL, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82
   PubMed Web of Science ®Google Scholar
• Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82
   PubMed Web of Science ®Google Scholar
• Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT and CAMIAT databases. Circulation 1999;99:2268-75
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. US5158964 (1992)
   Google Scholar
• Karo Bio. WO03009839 (2003)
   Google Scholar
• Bito V, Dauwe D, Verdonck F, Mubagwa K, Sipido KR. The amiodarone derivative KB130015 [2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran] induces an Na+-dependent increase of [Ca2+] in ventricular myocytes. J Pharmacol Exp Ther 2006;316:162-8
   PubMed Web of Science ®Google Scholar
• ISP Investments, Inc. WO03040120 (2003)
   Google Scholar
• Gautier P, Guillemare E, Marion A, et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Electrophysiol 2003;41:191-202
   Google Scholar
• Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol 2006;17:S17-20
   PubMed Web of Science ®Google Scholar
• Procter & Gamble Co. US6083945 (2000)
   Google Scholar
• Procter & Gamble Co. US2007021395 (2007)
   Google Scholar
• Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004;110:3646-54
   PubMed Web of Science ®Google Scholar
• Astrazeneca. WO2007069986 (2007)
   Google Scholar
• Astrazeneca. WO9931100 (1999)
   Google Scholar
• Cardiome Pharmaceutial Corporation. US2007197632 (2007)
   Google Scholar
• Bristol-Myers Squibb. US2007142333 (2007)
   Google Scholar
• Merck & Co., Inc. WO200750348 (2007)
   Google Scholar
• Isner JM. Myocardial gene therapy. Nature 2002;415:234-9
   PubMed Web of Science ®Google Scholar
• Hoshijima M. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol Ther 2005;105:211-8
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. WO02087419 (2002)
   Google Scholar
• Children's Hospital of Philadelphia. US2004087528 (2004)
   Google Scholar
• Johns Hopkins University. US2007048284 (2007)
   Google Scholar
• Kashiwakura Y, Cho HC, Barth AS, Azene E, Marban E. Gene transfer of a synthetic pacemaker channel into the heart: a novel strategy for biological pacing. Circulation 2006;114:1682-6
   Google Scholar
• Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 2006;12:1256-8
   PubMed Web of Science ®Google Scholar
• Merillat J, Lakatta EG, Hano O, Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res 1990;67:1115-23
   PubMedGoogle Scholar
• Kafiluddi R, Kennedy RH, Seifen E. Effects of ryanodine on inotropic and arrhythmogenic actions of cardiotonic steroids. Eur J Pharmacol 1986;131:273-8
   Google Scholar
• Kusuoka H, Jacobus WE, Marban E. Calcium oscillations in digitalis-induced ventricular fibrillation: pathogenic role and metabolic consequences in isolated ferret hearts. Circ Res 1988;62:609-19
   Google Scholar
• Zealand Pharmaceuticals. WO2005061437 (2005)
   Google Scholar
• Zealand Pharmaceuticals. WO03063891 (2003)
   Google Scholar
• Eloff BC, Gilat E, Wan X, Rosenbaum DS. Pharmacological modulation of cardiac gap junctions to enhance cardiac contraction. Circulation 2003;108:3157-63
   PubMed Web of Science ®Google Scholar
• Hennan JK, Swillo RE, Morgan GE, et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 2006;317:236-43
   Google Scholar
• Haugan K, Olsen KB, Hartvig L, et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Pharmacol 2005;16:537-45
   Google Scholar
• Clarke TC, Thomas D, Petersen JS, Evans WH, Martin PE. The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol 2006;147:486-95
   PubMed Web of Science ®Google Scholar
• Zealand Pharmaceuticals. WO2004048400 (2004)
   Google Scholar
• Zealand Pharmaceuticals, Wyeth Corporation. WO2007078990 (2007)
   Google Scholar
• Dhein S. Pharmacology of gap junctions in the cardiovascular system. Cardiovasc Res 2004;62:287-98
   PubMed Web of Science ®Google Scholar
• Medicure International, Inc. WO2007059631 (2007)
   Google Scholar
• Jiang H, Zhu AG, Mamczur M, et al. Stimulation of rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol 2007;151:1033-40
   PubMedGoogle Scholar
• Otsuka Pharmaceutical Co. WO9406427 (1994)
   Google Scholar
• Syntex, Inc. WO9403425 (1994)
   Google Scholar
• University of Texas, Myogen, Inc. WO2005049084 (2005)
   Google Scholar
• Harks EGA, Camina JP, Peters PHJ, et al. Besides affecting intracellular calcium signaling, 2-APB reversibly blocks gap junctional coupling in confluent monolayers, thereby allowing the measurement of single-cell membrane currents in undissociated cells. FASEB J 2003; DOI:10.1096/fj.02-0786fje
   Google Scholar
• Bai D, Del Corsso C, Srinivas M, Spray DC. Block of specific gap junction channel subtypes by 2-aminoethoxydiphenyl borate (2-APB). J Pharmacol Exp Ther 2006;319:1452-8
   PubMedGoogle Scholar
• Tao L, Harris AL. 2-Aminoethoxydiphenyl borate directly inhibits channels composed of connexin 26 and/or connexin 32. Mol Pharmacol 2007;71:570-9
   PubMedGoogle Scholar
• Huang YJ, Maruyama Y, Dvoryanchikov G, et al. The role of pannexin 1 hemichannels in ATP release and cell–cell communcation in mouse taste buds. Proc Natl Acad Sci USA 2007;104:6436-41
   PubMed Web of Science ®Google Scholar
• Locovei S, Bao L, Dahl G. Pannexin 1 in erythrocytes: function without a gap. Proc Natl Acad Sci USA 2006;103:7655-9
   PubMed Web of Science ®Google Scholar
• Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon hemichannels. Nat Rev Mol Cell Biol 2003;4:1-10
   Web of Science ®Google Scholar
• Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J 2006;397:1-14
   PubMed Web of Science ®Google Scholar
• George CH. Sarcoplasmic reticulum Ca2+ leak in heart failure: mere observation or functional relevance? Cardiovasc Res 2008; In Press. Doi:10.1093/cvr/cvm1006
   Google Scholar
• Anderson ME. Multiple downstream proarrhythmic targets for calmodulin kinase II: moving beyond an ion channel-centric focus. Cardiovasc Res 2007;73:657-66
   PubMed Web of Science ®Google Scholar
• Maier LS, Bers DM. Calcium, calmodulin, and calcium-calmodulin kinase II: heartbeat to heartbeat and beyond. J Mol Cell Cardiol 2002;34:919-39
   PubMed Web of Science ®Google Scholar
• Kaneko N. New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac death and intracellular calcium blocking action. Drug Develop Res 1994;33:429-38
   Web of Science ®Google Scholar
• Japan Tobacco Co. WO9212148 (1992)
   Google Scholar
• Columbia University. WO2006101497 (2006)
   Google Scholar
• Columbia University. WO2005094457 (2005)
   Google Scholar
• Ono K, Yano M, Ohkusa T, et al. Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca2+ release in heart failure. Cardiovasc Res 2000;48:323-31
   PubMedGoogle Scholar
• Kohno M, Yano M, Kobayashi S, et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol 2003;284:H1035-42
   PubMed Web of Science ®Google Scholar
• Wehrens XHT, Lehnart SE, Reiken SR, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin 2. Science 2004;304:292-6
   PubMed Web of Science ®Google Scholar
• Yano M, Yamamoto T, Ikeda Y, Matsuzaki M. Mechanisms of disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Prac Cardiovasc Med 2006;3:43-52
   PubMedGoogle Scholar
• Columbia University. US2007173482 (2007)
   Google Scholar
• Columbia University. WO2005037195 (2005)
   Google Scholar
• Columbia University. WO2004080283 (2004)
   Google Scholar
• Lisy O, Burnett JC. New cardioprotective agent K201 is natriuretic and glomerular filtration rate enhancing. Circulation 2006;113:246-51
   Google Scholar
• Inagaki K, Kihara Y, Izumi T, Sasayama S. The cardioprotective effects of a new 1,4-benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload in isolated rat hearts. Cardiovasc Drugs Ther 2000;14:489-95
   PubMedGoogle Scholar
• Tse HF, Lam WF. JTV-519 Japan tobacco. Curr Opin Investig Drugs 2001;2:936-9
   Google Scholar
• Guo T, Zhang T, Mestril R, Bers DM. Ca/Calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res 2006;99:398-406
   PubMed Web of Science ®Google Scholar
• Kockskamper J, Pieske B. Phosphorylation of the cardiac ryanodine receptor by Ca2+ /Calmodulin-dependent protein kinase II: the dominating twin of protein kinase A. Circ Res 2006;99:333-5
   Google Scholar
• Khoo MSC, Li J, Singh MV, et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 2006;114:1352-9
   PubMed Web of Science ®Google Scholar
• Leland Stanford Junior University. US2003134777 (2003)
   Google Scholar
• Vanderbilt University. US2004266675 (2004)
   Google Scholar
• University of Alabama at Birmingham. US2003153951 (2003)
   Google Scholar
• Li J, Marionneau C, Zhang R, et al. Calmodulin kinase II inhibition shortens action potential duration by upregulation of K+ currents. Circ Res 2006;99:1092-9
   PubMed Web of Science ®Google Scholar
• Zima A, Kockskamper J, Blatter LA. Cytosolic energy reserves determine the effect of glycolytic sugar phosphates on sarcoplasmic reticulum Ca2+ release in cat ventricular myocytes. J Physiol 2006;577:281-93
   Google Scholar
• Zima AV, Blatter LA. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006;71:310-21
   PubMed Web of Science ®Google Scholar
• Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004;555:1-13
   PubMed Web of Science ®Google Scholar
• Gazmuri RJ, Ayoub IM, Hoffner E, Kolarova JD. Successful ventricular defibrillation by the selective sodium-hydrogen exchanger isoform-1 inhibitor cariporide. Circulation 2001;104:234-9
   PubMed Web of Science ®Google Scholar
• Ayoub IM, Kolarova J, Yi Z, et al. Sodium-hydrogen exchange inhibition during ventricular fibrillation: beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitibility. Circulation 2003;107:1804-9
   Google Scholar
• Xue YX, Aye NN, Hashimoto K. Antiarrhythmic effects of HOE642, a novel Na+/H+ exchange inhibitor, on ventricular arrhythmias in animal hearts. Eur J Pharmacol 1996;317:309-16
   PubMed Web of Science ®Google Scholar
• Landmesser U, Drexler H. Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat Clin Prac Cardiovasc Med 2005;2:628-38
   Google Scholar
• Tokuhisa T, Yano M, Obayashi M, et al. AT1 receptor antagonist restores cardiac ryanodine receptor function, rendering isoproterenol-induced failing heart less susceptible to Ca2+ leak induced by oxidative stress. Circ J 2006;70:777-86
   PubMed Web of Science ®Google Scholar
• Baltogiannis GG, Tsalikakis DG, Mitsi AC, et al. Endothelin receptor A blockade decreases ventricular arrhythmias after myocardial infarction in rats. Cardiovasc Res 2005;67:647-54
   PubMed Web of Science ®Google Scholar
• Crockett TR, Scott GA, McGowan NW, Kane KA, Wainwright CL. Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721. Eur J Pharmacol 2001;432:71-7
   PubMed Web of Science ®Google Scholar
• Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB209670. J Pharmacol Exp Ther 2000;292:449-59
   PubMed Web of Science ®Google Scholar
• Ishizawa M, Mizushige K, Noma T, et al. An antioxidant treatment potentially protects myocardial energy metabolism by regulating uncoupling protein 2 expression in a chronic beta-adrenergic stimulation rat model. Life Sci 2006;78:2974-82
   Google Scholar
• Freudenberger RS, Schwarz RPJ, Brown J, et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. Expert Opin Investig Drugs 2004;13:1509-16
   PubMed Web of Science ®Google Scholar
• Cardiome Pharma Corp. press release: Cardiome Reports Clinical Results From OPT-CHF Study. Available from: http://cardiome.com/wordpress/?p=252
   Google Scholar
• Mitsubishi Pharmaceutical Co. WO03080583 (2003)
   Google Scholar
• Mitsubishi Pharmaceutical Co. WO2006016707 (2006)
   Google Scholar
• Edaravone Acute Infarction Study Group. Effect of a novel free scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222-9
   Google Scholar
• Yano M, Okuda S, Oda T, et al. Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 2005;112:3633-43
   PubMed Web of Science ®Google Scholar
• Yagi H, Horinaka S, Matsuoka H. Edaravone prevented deteriorated cardiac function after myocardial ishemia–reperfusion via inhibiting lipid peroxidation in rat. J Cardiovasc Electrophysiol 2005;46:46-51
   Google Scholar
• Yamawaki M, Sasaki N, Shimoyama M, et al. Protective effect of edaravone against hypoxia-reoxygenation injury in rabbit cardiomyocytes. Br J Pharmacol 2004;142:618-26
   PubMed Web of Science ®Google Scholar
• Neuromed Pharmaceutical Ltd. WO200145709 (2007)
   Google Scholar
• Takeda Pharmaceutical Co. WO2007077961 (2007)
   Google Scholar
• Neuromed Technologies, Inc. WO2007071035 (2001)
   Google Scholar
• Johns Hopkins University. WO2006138487 (2006)
   Google Scholar
• Johns Hopkins University. US2002091144 (2006)
   Google Scholar
• Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 2005;12:1528-34
   PubMed Web of Science ®Google Scholar
• Faust Pharmaceuticals. WO2007071379 (2007)
   Google Scholar
• Ellenbogen KA, O'Neill G, Prystowsky EN, et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 2005;111:3202-8
   PubMed Web of Science ®Google Scholar
• Peterman C, Sanoski CA. Tecadenoson: a novel, selective A1 adenosine receptor antagonist. Cardiol Rev 2005;13:315-21
   PubMedGoogle Scholar
• Kyowa Hakko Kogyo KK. EP0619316 (1994)
   Google Scholar
• Janssen Pharmaceutica. WO2007081995 (2007)
   Google Scholar
• Lim M, Honisett S, Sparkes CD, et al. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004;109:1212-4
   PubMed Web of Science ®Google Scholar
• Sagami Chemical Research: JP10139664 (1998)
   Google Scholar
• Sagami Chemical Research. WO9420092 (1994)
   Google Scholar
• Massachusetts General Hospital. US5760081 (1998)
   Google Scholar
• Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
   PubMed Web of Science ®Google Scholar
• Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intake on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;ii:757-61
   PubMed Web of Science ®Google Scholar
• Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarcation: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nll'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903
   PubMed Web of Science ®Google Scholar
• Xiao YF, Ke Q, Chen Y, Morgan JP, Leaf A. Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells. Biochem Biophys Res Commun 2004;321:116-23
   PubMed Web of Science ®Google Scholar
• Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanisms of prevention of arrhythmias by n-3 fish oils. Circulation 2003;107:2646-52
   PubMed Web of Science ®Google Scholar
• Guizy M, Arias C, David M, Gonzalez T, Valenzuela C. Omega-3 and omega-6 polyunsaturated fatty acids block HERG channels. Am J Physiol Cell Physiol 2005;289:C1251-60
   PubMed Web of Science ®Google Scholar
• Avestha Gengraine Technologies. WO2007068997 (2007)
   Google Scholar
• Dsm NV. US2004059142 (2004)
   Google Scholar
• Resolvyx Pharmaceuticals. US2004044050 (2004)
   Google Scholar
• Suntory Ltd. WO2006019186 (2006)
   Google Scholar
• Burr ML, Dunstan FDJ, George CH. Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. J Membrane Biol 2005;206:155-63
   Google Scholar
• University of Leipzig: WO2007073730 (2007)
   Google Scholar
• Ali MS, Ibrahim SA, Jalil S, Choudhary MI. Ursolic acid: a potent inhibitor of superoxides produced in the cellular system. Phytother Res 2007;21:558-61
   PubMed Web of Science ®Google Scholar
• Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645-6
   PubMed Web of Science ®Google Scholar
• Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005;4:78-84
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83
   PubMed Web of Science ®Google Scholar